Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Continued...
Tau Capital PLC
12 April 2019
12 April 2019
Tau Capital plc
("Tau" or "the Company")
Directorate Changes
Tau Capital plc ("the Company") announces that Gerwyn Williams and Nigel Burton have been appointed as non-executive Directors with immediate e?ect. Gerwyn Williams will be the Company's Chairman. Terence Mahony and Philip Lambert have stepped down from the Company's Board with immediate effect.
Both Gerwyn Williams and Nigel Burton have participated in the Placing announced on 15 March 2019, which completed on 9 April 2019. At the time of agreeing to participate in the Placing, both were not directors of the Company. Gerwyn Williams is interested in 32,530,000 Ordinary Shares, which represents a value of $32,530 at the Placing price and represents 16.35% of the voting rights in the Company. Nigel Burton is interested in 26,024,000 Ordinary Shares, which represents a value of $26,024 at the Placing price and represents 13.08% of the voting rights in the Company.
Further to the Company's announcement of 15 March 2019, the Board has decided that it will defer any decision to change the name of the Company for the time being.
Gerwyn Llewellyn Williams (aged 69)
Gerwyn is a quali?ed Electrical Engineer with many years' hands on experience in the coal mining and unconventional gas industries, having started work as an underground mine worker spending 22 years working for British Coal. He has founded a number of energy businesses and is currently the largest shareholder in In?nity Energy and the company's Chief Executive O?cer. Gerwyn is also the Chairman of UK Onshore Gas, his family owned group of companies that hold 139,839 acres of Petroleum Exploration and Development Licences ("PEDL") in South Wales via wholly owned subsidiary companies Coastal Oil and Gas Limited, UK Methane Limited and Adamo Energy (UK) Limited. Gerwyn is also the sole Director of Transgas whose subsidiary South Western Energy Limited holds 203,590 acres of PEDLs in North Somerset and in Dorset adjacent to Wytch Farm. Transgas is wholly owned by the Williams family. Gerwyn is a Chartered Engineer, a Fellow of the Institute of Materials, Minerals and Mining, and a Fellow of the Energy Institute.
In accordance with Schedule 2(g) of the AIM Rules, Gerwyn Williams holds, or has held in the past ?ve years, the following directorships and partnerships:
Current
Adamo Energy (UK) Limited Air Nation Limited
Past five years Modal Mining Limited
Coastal Oil & Gas Limited Infinity Energy SA
Infinity Exploration Limited
Local Energy Supply Systems Limited Technoleg Limited
Newton Beach Development Company Limited
South Eastern Energy Limited
South Wales Energy Limited South Wales Gas Limited South Western Energy Limited St John's Vision Limited Thistle Gas Limited Topex Limited Transgas Limited UK Gas Limited
UK Methane Limited UK Onshore Gas Limited UK Water Supplies Limited UK Wind Energy Limited Sefydliad Tanwydd Cymru Cyf
26.3% holding
Waiting for the holdings rns
11-Apr-19 16:48:45 0.001 52,410,000 Sell* 0.0015 0.0025 52.41k O
11-Apr-19 16:46:06 0.001 52,410,000Sell* 0.0015 0.0025 52.41k O
Do you anyone who got it offered Apart from GW and NB parties???
Would like to ask what was the pitch
when the placees are in at 0.001
Please explain ...
Or are we talking Winston Wolf ?
:-)
Company name to "UK Onshore PLC
This one is much cleaner
Why do this if there is so much more elsewhere ?
He really is taking the piss and I think someone will end up giving him a bullet.
Gerwyn Williams and Nigel Burton appointed
Game on
Think everyone should vote no to sale resolution - Stolpharm is worth more.
hTTps://deepvalueinvestments.wordpress.com/2018/08/28/tau-vote-no-on-giveaway-sale/#more-2113
impairment out of the blue. all indicators were it was going well
im expecting a uplift
more vacancies and promotions and new look team profiles. expecting a big update here. plus new TR1 holder
https://astanatimes.com/2018/03/kazakh-domestic-pharmaceutical-production-up-79-8-percent-in-2017/ Kazakh domestic pharmaceutical production up 79.8 percent in 2017 By Yerbolat Uatkhanov in Business on 2 March 2018 ASTANA � The Kazakh pharmaceutical industry increased production of the country�s most popular medications by 73.1 percent with production increasing 79.8 percent over 2016. Prices for pharmaceutical products in Kazakhstan have also increased 6.6 percent over the last 12 months.The production increases are an attempt by the Kazakh pharmaceutical industry to replace imports with domestic production. Among the high production areas were the Almaty region (52.8 percent of total domestic production), the South Kazakhstan region (18.3 percent) and Almaty (12.4 percent). Such large companies as AbdiIbahim GlobalPharm, Kelun-KazPharm, Dolce, Zerde-Fito, Chimpharm, Nobel Almaty Pharmaceutical Factory, Aurora, Cheminnova Alimor Kazpharm, Rapid-Alimor Pharm Industries, Dosfarm have plants in the regions, energyprom.kz reports. SANTO company, being a part of the international pharmaceutical group Polpharma (Poland), is implementing the largest investment project in the South Kazakhstan region to modernise the existing pharmaceutical production of Chimpharm in accordance with English Good Manufacturing Practice (GMP) international standards. The Polish investor will invest $37 million in the plant. The main objectives of the fourth stage of the investment programme of Polpharma international group for 2018-2022 are the development of the IT infrastructure, digitisation of the production process, the improvement and automation of the quality control and quality assurance system and the development of new medicines. The company is going to build a new laboratory as well as update existing infrastructure, equipment and logistics facilities. Over the 11 months of 2017, 14.3 percent of antibiotics sold in Kazakhstan were produced domestically. However, domestic production of other pharmaceuticals reached 53.1 percent of the total Kazakh market.
Kazakh pharmaceutical company 'MEDSERVIS PLUS' - the largest national distributor of pharmaceuticals, medical devices and medical equipment in Kazakhstan. The company started its activities in 1995. One step at a time increasing turns, for 20 years has taken a strong position in the pharmaceutical market, has acquired a good reputation as a reliable business partner. The latest technologies, continuous expansion of the product range, good pricing and a clear fulfillment of obligations to clients - the main advantages of our company. We supply high-quality medicinal products in Kazakhstan and create all the necessary conditions for the storage and delivery of medication in each laboratory and medical establishment. Our work is aimed at improving the health of the population of the Republic of Kazakhstan, by ensuring access to quality medicines. PRINCIPAL ACTIVITIES 1. Wholesale trade in medicines 2. Integrated logistics services 3. Production of medicines. 4. Marketing and promotion of pharmaceutical products and medical devices. COMPETITIVE ADVANTAGES of MEDSERVICE PLUS 17 branches around Kazakhstan International standards GDP Implements sales forecast and financial procedures in SAP ERP HANA. Own warehouses 300 contracts with leading manufacturers 6000 products customer base 2500 drugstores and hospitals Has bonded warehouse. Has internal Training Department. Has Sales Department. Has own production plant, planning to start working at the 1st quarter of 2017. PARTNERS OF THE COMPANY LLP �MS STOCK international transport transport logistics customs representative services transportation of cargoes to Kazakhstan RETAIL NETWORK OF DRUGSTORES PHARMACOM Sale of medicines, para-pharmaceutical products, dietary supplements and related products in retail Vaccination for the prevention of and protection against harmful infectious diseases vaccines from leading manufacturers. Currently, there are 49 pharmacies and 3 vaccination clinics in major cities of Kazakhstan QUALITY MANAGEMENT SYSTEM In 2007, the year the Company LLP �KPC �MEDSERVICE PLUS�; has been certified to ISO 9001 2008 In 2011, the company LLP �KPC� MEDSERVIS PLUS '; It has been certified to ISO 9001 in 2009; 2013-2014 years implementation of standards of good practice drug distribution GDP (Good Distribution Practice) STRK 1614-2006
The Board remains of the view that it is in the best interests of shareholders to allow Stopharm to continue to develop its business further, which will hopefully improve its value and create the opportunity for our stake in Stopharm to be realised. The Board is of the opinion that the interests of shareholders are best served by continuing to actively pursue the sale of the Company's interest in Stopharm either directly or through other intermediaries
http://gulfnews.com/business/sectors/retail/walgreens-pumps-418m-into-china-s-top-pharmacy-chain-1.2137092 NEW YORK: Walgreens Boots Alliance Inc. took a 40 per cent stake in the leading retail-pharmacy network in China, boosting its investment in the country where an expanding middle-class consumer segment offers growth opportunities. The US drugstore chain will invest $418 million in Sinopharm Holding Guoda Drugstores Co., a subsidiary of China National Accord Medicines Corp. that has operated retail pharmacies across China since 2004, Walgreens said in a statement Wednesday. The Deerfield, Illinois-based company, which has been present in the Asian country for about a decade, said it�s �well positioned� to provide expertise to Guoda and support its growth. The deal is being forged as demand for medicines in the world�s second-biggest pharmaceutical market surges with an ageing population which faces rising rates of chronic diseases such as cancer and diabetes. A growing middle-class segment is also increasingly able to afford more expensive drugs including innovative treatments. �The emerging middle class is a fantastic favourable wind for the industry,� Stefano Pessina, chief executive officer of Walgreens, said in an interview with Bloomberg TV on Thursday, speaking from a conference in Guangzhou. �The market is changing, the separation between prescriptions and delivery created opportunities.� Shares of Walgreens rose 1.2 per cent in New York on Wednesday, paring the decline this year to 14 per cent. Sinopharm Group Co., the majority shareholder of Guoda�s owner China National Accord, rose as much as 4.5 per cent in Hong Kong on Thursday before paring gains to trade little changed at the midday break.
going to get to Ten grand quickly here
Think it ll be worth more if actual sale happens and itll be a cash sale Stopharm Stopharm is a wholesale pharmaceuticals distributor operating in Kazakhstan. The investment in Stopharm has been valued at 30 June 2017 at US$6,000,000 (31 December 2016: US$6,000,000; 30 June 2016: US$6,000,000). The valuation is based on an enterprise value, which is calculated on a multiple range of 6 to 16 times EBITDA. The multiple applied for the valuation is considered an area of significant judgement due to the lack of comparable listed companies or recent transactions involving similar businesses on which to determinate the multiple applied against earnings. The estimated values may differ materially from the value that would have been realised had a disposal of the private investment been made between a willing buyer and seller as at 30 June 2017, which in turn would have an impact on the valuation of the Company�s investment in subsidiaries. It is not possible to qualify such uncertainties.
The UAE and Kazakhstan yesterday signed six agreements (Saturday) on various areas of investment and business sectors. His Highness Shaikh Mohammad Bin Zayed Al Nahyan, Abu Dhabi Crown Prince and Deputy Supreme Commander of the UAE Armed Forces, and President Nursultan Nazarbayev of Kazakhstan attended the signing ceremony on the agreements. Among the deals DP World and Kazakhstan signed two framework agreements relating to the acquisition, governance and management of Special Economic Zones (SEZ) in Aktau and Khorgos. DP World has been providing management services to the Port of Aktau, Kazakhstan�s main cargo and bulk terminal on the Caspian Sea, and Khorgos SEZ, which is strategically situated on the China-Kazakhstan border and has been acting as the primary transit point for trans-Eurasian cargo trains for more than four years. DP World now plans to acquire a 51 per cent stake in the Khorgos SEZ and 49 per cent in the Aktau SEZ following the agreements signed today, to play an important role in enhancing trade connectivity along the New Silk Route, handling all cargo types including hydrocarbons, containers and bulk. The two agreements were signed between Sultan Ahmad Bin Sulayem, Group Chairman and CEO of DP World and Kanat Alpysbayev, President of Kazakhstan Temir Zholy (KTZ) and Yeraly Tugzhanov, Governor of the Mangistau region of Kazakhstan. An agreement on encouragement and mutual protection of investments was signed by Obiad Humaid Al Tayer, Minister of State for Financial Affairs, and Kazakh Minister of Investment and Development Kassymbek Zhenis Mahmudovich. Other agreements include setting up a polyethylene plant and a project to produce polypropylene in Kazakhstan. The two agreements were signed by Suhail Bin Mohammad Faraj Al Mazroui, Minister of Energy and Industry, and Kanat Aldabergenovich Bozumbayev, Kazakhstan�s minister of energy Another agreement was signed between the Expo 2020 Dubai Higher Committee and Kazakhstan�s government by Najeeb Mohammad Al Ali, Executive Director of the Expo 2020 Bureau, and Allen Chayzhunusov, Commissioner General of the Expo 2020 Dubai International Exhibition Kazakhstani Section.
Stopharm LLP Key Developments Stopharm LLP Reports Audited Earnings Results for the Year Ended 31 December 2016 Jun 30 17 Stopharm LLP reported audited earnings results for the year ended 31 December 2016. For the year, the company reported revenues of USD 127,561,000 compared to USD 109,730,000 a year ago. EBITDA was USD 4,425,000 compared to USD 3,010,000 a year ago. Net profit was USD 1,108,000 compared to USD 227,000 a year ago. Stopharm LLP Reports Earnings Results for the Six Months Ended June 30, 2016; Provides Earnings Guidance for the Full Year of 2016 Sep 30 16 Stopharm LLP reported earnings results for the six months ended June 30, 2016. For the period, the company reported revenues of USD 64,758,000, EBITDA of USD 2,273,000 and net profit of USD 961,000. For the full year of 2016, the company expects revenues of USD 129,500,000, EBITDA of USD 4,500,000 and net profit of USD 1,922,000.
Kazakh domestic pharmaceutical production up 79.8 percent in 2017 By Yerbolat Uatkhanov in Business on 2 March 2018 ASTANA � The Kazakh pharmaceutical industry increased production of the country�s most popular medications by 73.1 percent with production increasing 79.8 percent over 2016. Prices for pharmaceutical products in Kazakhstan have also increased 6.6 percent over the last 12 months. The production increases are an attempt by the Kazakh pharmaceutical industry to replace imports with domestic production. Among the high production areas were the Almaty region (52.8 percent of total domestic production), the South Kazakhstan region (18.3 percent) and Almaty (12.4 percent). Such large companies as AbdiIbahim GlobalPharm, Kelun-KazPharm, Dolce, Zerde-Fito, Chimpharm, Nobel Almaty Pharmaceutical Factory, Aurora, Cheminnova Alimor Kazpharm, Rapid-Alimor Pharm Industries, Dosfarm have plants in the regions, energyprom.kz reports. SANTO company, being a part of the international pharmaceutical group Polpharma (Poland), is implementing the largest investment project in the South Kazakhstan region to modernise the existing pharmaceutical production of Chimpharm in accordance with English Good Manufacturing Practice (GMP) international standards. The Polish investor will invest $37 million in the plant. The main objectives of the fourth stage of the investment programme of Polpharma international group for 2018-2022 are the development of the IT infrastructure, digitisation of the production process, the improvement and automation of the quality control and quality assurance system and the development of new medicines. The company is going to build a new laboratory as well as update existing infrastructure, equipment and logistics facilities. Over the 11 months of 2017, 14.3 percent of antibiotics sold in Kazakhstan were produced domestically. However, domestic production of other pharmaceuticals reached 53.1 percent of the total Kazakh market. Vitamins and their derivatives are not produced in Kazakhstan. Prices for imported vitamins increased 5.6 percent over 2016. Prices for hormonal drugs also rose 21.6 percent, analgesics 12.9 percent and gastric drugs 7.5 percent.
Which means 77% not in public hands...